- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
John Orwin, Genentech
S
ONE TO WATCH:
John Orwin, SVP, Sales and Marketing, BioOncology, Genentech
Orwin learned the landscape of onoclogy while working as senior director of oncology marketing at Alza, and then eventually as the franchise VP at J&J's Tibotec division. In 2005, he headed out to Cali to join Genentech, and was promoted the same year to head sales and marketing of its BioOncology division. And it's a good thing: Orwin was part of the commercial genius that built such heavyweights as Avastin, Herceptin, and Rituxan.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
